| Name | Walgreens #9028 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 6700 Ritchie Hwy, Glen Burnie, Maryland 21061 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (443) 848-0245 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).
Researchers have developed a simple tool that predicts virologic response and development of drug resistance in patients receiving HIV treatment, based on how regularly they attend their scheduled health appointments.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.
A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.
› Verified 2 days ago
| NPI Number | 1134136211 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #09028 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 6700 Ritchie Hwy, Glen Burnie, MD 21061 |
| Phone Number | 443-848-0245 |
News Archive
Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).
Researchers have developed a simple tool that predicts virologic response and development of drug resistance in patients receiving HIV treatment, based on how regularly they attend their scheduled health appointments.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.
A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.
› Verified 2 days ago
News Archive
Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).
Researchers have developed a simple tool that predicts virologic response and development of drug resistance in patients receiving HIV treatment, based on how regularly they attend their scheduled health appointments.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.
A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.
› Verified 2 days ago
Rite Aid Pharmacy 01859 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7501 Ritchie Hwy, Glen Burnie, Maryland 21061 Phone: (410) 766-5220 | |
Rite Aid Pharmacy 03781 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7967 Baltimore Annapolis Blvd, Glen Burnie, Maryland 21060 Phone: (410) 768-3875 | |
Rotech Type: Durable Medical Equipment & Medical Supplies Supplier Location: 810 Cromwell Park Dr, Glen Burnie, Maryland 21061 Phone: (301) 362-7600 | |
Care Rx Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 325 Hospital Dr, Glen Burnie, Maryland 21061 Phone: (410) 768-1212 | |
Cvs Pharmacy #01735 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7400 Ritchie Hwy, Glen Burnie, Maryland 21061 Phone: (410) 760-2112 |